AR112448A1 - Derivados de xantina sustituidos - Google Patents

Derivados de xantina sustituidos

Info

Publication number
AR112448A1
AR112448A1 ARP180101931A AR112448A1 AR 112448 A1 AR112448 A1 AR 112448A1 AR P180101931 A ARP180101931 A AR P180101931A AR 112448 A1 AR112448 A1 AR 112448A1
Authority
AR
Argentina
Prior art keywords
xanthine derivatives
substituted xanthine
group
substituted
trpc5
Prior art date
Application number
Other languages
English (en)
Inventor
Bertrand Chenard
Stefan Just
Achim Sauer
Christian Eickmeier
Kai Gerlach
Original Assignee
Boehringer Ingelheim Int
Hydra Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Hydra Biosciences Inc filed Critical Boehringer Ingelheim Int
Publication of AR112448A1 publication Critical patent/AR112448A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud se refiere a derivados de xantina sustituidos, a composiciones farmacéuticas que los contienen y a su uso en terapia, particularmente en el tratamiento de afecciones que tienen una asociación con los canales iónicos que contienen TRPC5. Reivindicación 1: Un compuesto seleccionado del grupo que consiste en: el grupo de fórmulas (1).
ARP180101931 2017-07-11 2018-07-11 Derivados de xantina sustituidos AR112448A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17180721 2017-07-11

Publications (1)

Publication Number Publication Date
AR112448A1 true AR112448A1 (es) 2019-10-30

Family

ID=59325162

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101931 AR112448A1 (es) 2017-07-11 2018-07-11 Derivados de xantina sustituidos

Country Status (30)

Country Link
US (1) US10329292B2 (es)
EP (1) EP3652176B1 (es)
JP (1) JP7114702B2 (es)
KR (1) KR20200030048A (es)
CN (1) CN110997675B (es)
AR (1) AR112448A1 (es)
AU (1) AU2018299824B2 (es)
BR (1) BR112019025611A2 (es)
CA (1) CA3066922A1 (es)
CL (1) CL2020000056A1 (es)
CO (1) CO2019015102A2 (es)
CY (1) CY1125014T1 (es)
DK (1) DK3652176T3 (es)
EA (1) EA039526B1 (es)
ES (1) ES2903268T3 (es)
HR (1) HRP20220029T1 (es)
HU (1) HUE057600T2 (es)
IL (1) IL271799B (es)
LT (1) LT3652176T (es)
MX (1) MX2020000402A (es)
PH (1) PH12020500079A1 (es)
PL (1) PL3652176T3 (es)
PT (1) PT3652176T (es)
RS (1) RS62826B1 (es)
SA (1) SA519410851B1 (es)
SG (1) SG11201912168TA (es)
SI (1) SI3652176T1 (es)
TW (1) TWI801398B (es)
UA (1) UA124793C2 (es)
WO (1) WO2019011802A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019396499A1 (en) * 2018-12-12 2021-05-27 Boehringer Ingelheim International Gmbh Substituted xanthine derivatives
CN113166150B (zh) * 2018-12-12 2023-12-01 勃林格殷格翰国际有限公司 经取代的黄嘌呤衍生物
AU2020357178A1 (en) * 2019-10-04 2022-05-12 Goldfinch Bio, Inc. Biomarker-based treatment of focal segmental glomerulosclerosis and diabetic kidney disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230382B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
KR20090029299A (ko) * 2006-07-14 2009-03-20 화이자 프로덕츠 인코포레이티드 (7ｓ)-7-[(5-플루오로-2-메틸-벤질)옥시]-2-[(2ｒ)-2-메틸피페라진-1-일]-6,7-다이하이드로-5ｈ-사이클로펜타[ｂ]피리딘의 타르트레이트 염
CA2899646C (en) 2013-03-15 2021-08-31 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
EP3180342B1 (en) * 2014-08-11 2019-06-26 Hydra Biosciences, Inc. Pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione derivatives
JP6667093B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
JP6559228B2 (ja) 2014-09-17 2019-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症及び糖尿病の治療に有用なテトラヒドロイソキノリン誘導体及び医薬組成物

Also Published As

Publication number Publication date
CO2019015102A2 (es) 2020-05-15
EP3652176B1 (en) 2021-12-15
JP7114702B2 (ja) 2022-08-08
WO2019011802A1 (en) 2019-01-17
JP2020526591A (ja) 2020-08-31
PH12020500079A1 (en) 2020-10-05
HUE057600T2 (hu) 2022-05-28
US10329292B2 (en) 2019-06-25
IL271799A (en) 2020-02-27
TW201908318A (zh) 2019-03-01
US20190016722A1 (en) 2019-01-17
CN110997675B (zh) 2022-06-07
CN110997675A (zh) 2020-04-10
IL271799B (en) 2022-08-01
AU2018299824A1 (en) 2019-12-19
SG11201912168TA (en) 2020-01-30
SI3652176T1 (sl) 2022-04-29
RS62826B1 (sr) 2022-02-28
SA519410851B1 (ar) 2023-02-26
HRP20220029T1 (hr) 2022-04-15
CA3066922A1 (en) 2019-01-17
EA039526B1 (ru) 2022-02-07
AU2018299824B2 (en) 2022-06-16
DK3652176T3 (da) 2022-01-17
MX2020000402A (es) 2020-08-17
EA202090270A1 (ru) 2020-04-24
CL2020000056A1 (es) 2020-06-12
KR20200030048A (ko) 2020-03-19
EP3652176A1 (en) 2020-05-20
BR112019025611A2 (pt) 2020-06-16
PT3652176T (pt) 2022-01-13
ES2903268T3 (es) 2022-03-31
TWI801398B (zh) 2023-05-11
UA124793C2 (uk) 2021-11-17
CY1125014T1 (el) 2023-03-24
LT3652176T (lt) 2022-02-25
PL3652176T3 (pl) 2022-04-04

Similar Documents

Publication Publication Date Title
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2020001271A1 (es) Inhibidores de kras g12c
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2019000941A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
UY37952A (es) Formulaciones de un inhibidor de la quinasa trk macrocíclica
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
UY37098A (es) Moduladores de ror-gamma
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
CR20180034A (es) Derivados de glucagón y una composición que comprende un conjugado de acción prolongada del mismo.
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
PE20210452A1 (es) Inhibidores de la arginasa
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2019001993A1 (es) Inhibidores selectivos de jak1.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2016001937A1 (es) Compuestos de benzopirano funcionalizados y uso de los mismos
AR112448A1 (es) Derivados de xantina sustituidos
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
CO2018008445A2 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-deca
ECSP16096831A (es) Derivados de naftiridinadiona
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction